Sonidegib diphosphate是一种强效且选择性的 Smo 抑制剂，在小鼠和人类 Smo 的结合实验中的 IC50 分别为 1.3 nM 和 2.5 nM。
HazMat Fee +
There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type
HazMat fee for 500 gram (Estimated)
Excepted Quantity
USD 0.00
Limited Quantity
USD 15-60
Inaccessible (Haz class 6.1), Domestic
USD 80+
Inaccessible (Haz class 6.1), International
USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic
USD 100+
Accessible (Haz class 3, 4, 5 or 8), International
LDE225 diphosphate is a potent and selective Smo antagonist with IC50 of 1.3 nM and 2.5 nM for mouse and human Smo in binding assay, respectively.
Sonidegib diphosphate 细胞实验
Cell Line
Concentration
Treated Time
Description
References
BV2 microglial cells
10 µM
24 hours
Inhibited LPS-induced JNK phosphorylation
Int J Mol Sci. 2022 Sep 13;23(18):10590
BV2 microglial cells
10 µM
24 hours
Inhibited the LPS-induced IκBα phosphorylation and NF-κB nuclear translocation
Int J Mol Sci. 2022 Sep 13;23(18):10590
BV2 microglial cells
10 µM
24 hours
Inhibited the LPS-induced expression of iNOS and COX-2
Int J Mol Sci. 2022 Sep 13;23(18):10590
BV2 microglial cells
10 µM
24 hours
Suppressed LPS-stimulated cell migration
Int J Mol Sci. 2022 Sep 13;23(18):10590
BV2 microglial cells
10 µM
24 hours
Inhibited LPS-induced MKK4 phosphorylation
Int J Mol Sci. 2022 Sep 13;23(18):10590
BV2 microglial cells
10 µM
24 hours
Inhibited LPS-induced c-Jun phosphorylation
Int J Mol Sci. 2022 Sep 13;23(18):10590
BV2 microglial cells
30 µM
24 hours
Reduced the LPS-induced production of IL-1β, IL-6, TNF-α, and NO
Int J Mol Sci. 2022 Sep 13;23(18):10590
HS-5 cells
10 µM
48 hours
To investigate the effect of Sonidegib on the adhesion of HS-5 bone marrow stromal spheroids to OCI-AML3 cells. Results showed that Sonidegib significantly prolonged the contact time required for leukemia cells to establish adhesive connections with the bone marrow stromal spheroid.
Biomedicines. 2025 Feb 25;13(3):578
OCI-AML3 cells
10 µM
48 hours
To investigate the effect of Sonidegib on the adhesion of OCI-AML3 cells to HS-5 bone marrow stromal spheroids. Results showed that Sonidegib significantly increased the minimum cell-to-cell adhesion time required for leukemic cells to establish adhesive bonds with bone marrow stromal cells, indicating a reduction in their adhesive properties.
Biomedicines. 2025 Feb 25;13(3):578
Sonidegib diphosphate 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Human
Patients with locally advanced basal cell carcinoma
Oral
200 mg/day
Once daily for a median duration of 7.8 months (range 6-11 months)
To evaluate the efficacy and safety of Sonidegib alone or in combination with surgical excision for the treatment of locally advanced basal cell carcinomas. Results showed that 15 out of 29 lesions treated with Sonidegib alone achieved complete remission (CR), and 14 had partial remission (PR). All lesions treated with Sonidegib in association with surgical excision achieved CR.
Oncologist. 2022 Jun 8;27(6):e533
ICR mice
LPS-induced neuroinflammation model
Oral
40 mg/kg
Once daily for 7 days
Attenuated IL-6 and TNF-α levels in the brains of LPS-treated mice
Int J Mol Sci. 2022 Sep 13;23(18):10590
BALB/c mice
Breast cancer bone metastasis model
Oral
50 mg/kg
Once daily until the mice were sacrificed
To evaluate the inhibitory effect of Sonidegib on breast cancer bone metastasis. Sonidegib treatment reduced ALP expression around tumor cells and recovered NK cell infiltration in bone lesions, leading to alleviated bone metastasis burden, and extended survival of the mice.
搜索
HazMat Fee +
